{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:35:48Z","timestamp":1790260548367,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T00:00:00Z","timestamp":1682640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T00:00:00Z","timestamp":1682640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Recent studies have indicated some differences in the prognosis of patients with stage III-N2 lung adenocarcinoma, and the prognosis of patients with skip N2 lymph node metastasis (SKN2) is good. This study grouped patients with stage III-N2 lung adenocarcinoma by propensity score matching (PSM) to evaluate the impact of SKN2 on the prognosis of these patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The clinical data for patients who underwent radical lobectomy and had a postoperative pathological diagnosis of stage III-N2 lung adenocarcinoma at our centre from 2016 to 2018 were collected, and PSM was performed at a ratio of 1:1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 456 patients were enrolled in this study. After PSM, 112 patients were included in the SKN2 group, and 112 patients were included in the non-SKN2 group. When comparing the SKN2 group with the non-SKN2 group, the 3-year OS rate was (71.4% vs. 12.5%, p\u2009&lt;\u20090.001), and the 3-year DFS rate was (35.7% vs. 5.4%, p\u2009&lt;\u20090.001). It is further divided into four groups:single-station SKN2 (N2a1),Multi-station SKN2 (N2a2),single-station non-SKN2 (N2b1) and Multi-station non-SKN2 (N2b2).The 3-year OS and DFS rates of skip lymph node metastasis were better than those of non-skip lymph node metastasis(OS:N2a1 vs. N2b1 68.4% vs. 23.5%,p\u2009&lt;\u20090.001;N2a2 vs. N2b2 73.0% vs. 7.7%,p\u2009&lt;\u20090.001)(DFS:N2a1 vs. N2b1 68.4% vs. 5.9%,p\u2009&lt;\u20090.001;N2a2 vs. N2b2 62.2% vs. 5.1%,p\u2009&lt;\u20090.001), regardless of the number of N2 station(OS:N2a1 vs. N2a2 68.4% vs. 73.0%,p\u2009=\u20090.584;N2b1 vs. N2b2 23.5% vs. 7.7%,p\u2009=\u20090.051). On multivariate analysis, sex (p\u2009=\u20090.008) ,Vascular tumour thrombus(p\u2009=\u20090.047),size(p\u2009=\u20090.002)and SKN2 (p\u2009&lt;\u20090.001) were independent predictors of OS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>For patients with stage III-N2 lung adenocarcinoma, the prognosis of SKN2 patients is better than non-SKN2 patients\u2019, and SKN2 may be used as an important factor in the N2 subgroup classification in future TNM staging.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12890-023-02437-0","type":"journal-article","created":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T08:03:09Z","timestamp":1682668989000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Role of skip N2 lymph node metastasis for patients with the stage III-N2 lung adenocarcinoma: a propensity score matching analysis"],"prefix":"10.1186","volume":"23","author":[{"given":"Shize","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaonan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqing","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maogang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6797-6783","authenticated-orcid":false,"given":"Qingyi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,28]]},"reference":[{"issue":"1","key":"2437_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7\u201333.","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"2437_CR2","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1097\/JTO.0000000000000678","volume":"10","author":"H Asamura","year":"2015","unstructured":"Asamura H, Chansky K, Crowley J, et al. The International Association for the study of Lung Cancer Lung Cancer Staging Project: proposals for the revision of the N descriptors in the Forthcoming 8th Edition of the TNM classification for Lung Cancer. J Thorac Oncol. 2015;10(12):1675\u201384.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"2437_CR3","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1148\/radiol.2021204461","volume":"300","author":"H Song","year":"2021","unstructured":"Song H, Yoon SH, Kim J, et al. Application of N descriptors proposed by the International Association for the study of Lung Cancer in Clinical Staging. Radiology. 2021;300(2):450\u20137.","journal-title":"Radiology"},{"issue":"11","key":"2437_CR4","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1016\/j.jtho.2019.07.034","volume":"14","author":"BJ Park","year":"2019","unstructured":"Park BJ, Kim TH, Shin S, et al. Recommended change in the N descriptor proposed by the International Association for the study of Lung Cancer: a validation study. J Thorac Oncol. 2019;14(11):1962\u20139.","journal-title":"J Thorac Oncol"},{"issue":"5","key":"2437_CR5","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1093\/ejcts\/ezz147","volume":"56","author":"JK Yun","year":"2019","unstructured":"Yun JK, Lee GD, Choi S, et al. Comparison between lymph node station- and zone-based classification for the future revision of node descriptors proposed by the International Association for the study of Lung Cancer in surgically resected patients with non-small-cell lung cancer. Eur J Cardiothorac Surg. 2019;56(5):849\u201357.","journal-title":"Eur J Cardiothorac Surg"},{"issue":"1","key":"2437_CR6","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.athoracsur.2004.06.081","volume":"79","author":"M Riquet","year":"2005","unstructured":"Riquet M, Assouad J, Bagan P, et al. Skip mediastinal lymph node metastasis and lung cancer: a particular N2 subgroup with a better prognosis. Ann Thorac Surg. 2005;79(1):225\u201333.","journal-title":"Ann Thorac Surg"},{"issue":"4","key":"2437_CR7","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1093\/ejcts\/ezu244","volume":"47","author":"A Gorai","year":"2015","unstructured":"Gorai A, Sakao Y, Kuroda H, et al. The clinicopathological features associated with skip N2 metastases in patients with clinical stage IA non-small-cell lung cancer. Eur J Cardiothorac Surg. 2015;47(4):653\u20138.","journal-title":"Eur J Cardiothorac Surg"},{"key":"2437_CR8","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.lungcan.2020.11.005","volume":"151","author":"T Tsitsias","year":"2021","unstructured":"Tsitsias T, Okiror L, Veres L, et al. New N1\/N2 classification and lobe specific lymphatic drainage: impact on survival in patients with non-small cell lung cancer treated with surgery. Lung Cancer. 2021;151:84\u201390.","journal-title":"Lung Cancer"},{"issue":"2","key":"2437_CR9","first-page":"100019","volume":"1","author":"J Abe","year":"2020","unstructured":"Abe J, Matsumura Y, Shiono S, et al. Validation of the proposed cN2 subclassification in the Eighth Edition of the IASLC Staging System: a prospective phase II Multicenter Study. JTO Clin Res Rep. 2020;1(2):100019.","journal-title":"JTO Clin Res Rep"},{"issue":"3","key":"2437_CR10","doi-asserted-by":"publisher","first-page":"217","DOI":"10.5761\/atcs.oa.14-00218","volume":"21","author":"K Kawasaki","year":"2015","unstructured":"Kawasaki K, Sato Y, Suzuki Y, Saito H, Nomura Y, Yoshida Y. Prognostic factors for surgically resected N2 non-small cell Lung Cancer. Ann Thorac Cardiovasc Surg. 2015;21(3):217\u201322.","journal-title":"Ann Thorac Cardiovasc Surg"},{"issue":"5","key":"2437_CR11","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1097\/JTO.0b013e3181a0d82e","volume":"4","author":"VW Rusch","year":"2009","unstructured":"Rusch VW, Asamura H, Watanabe H, Giroux DJ, Rami-Porta R, Goldstraw P. The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol. 2009;4(5):568\u201377.","journal-title":"J Thorac Oncol"},{"issue":"12","key":"2437_CR12","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1007\/s00432-008-0421-3","volume":"134","author":"K Ma","year":"2008","unstructured":"Ma K, Chang D, He B, et al. Radical systematic mediastinal lymphadenectomy versus mediastinal lymph node sampling in patients with clinical stage IA and pathological stage T1 non-small cell lung cancer. J Cancer Res Clin Oncol. 2008;134(12):1289\u201395.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"11","key":"2437_CR13","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1200\/JCO.2016.67.5140","volume":"35","author":"W Liang","year":"2017","unstructured":"Liang W, He J, Shen Y, et al. Impact of examined Lymph Node count on Precise Staging and Long-Term Survival of Resected Non-Small-Cell Lung Cancer: a Population Study of the US SEER database and a chinese multi-institutional Registry. J Clin Oncol. 2017;35(11):1162\u201370.","journal-title":"J Clin Oncol"},{"issue":"4","key":"2437_CR14","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.jtcvs.2015.03.067","volume":"150","author":"H Li","year":"2015","unstructured":"Li H, Hu H, Wang R, et al. Lung adenocarcinoma: are skip N2 metastases different from non-skip. J Thorac Cardiovasc Surg. 2015;150(4):790\u20135.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"3","key":"2437_CR15","doi-asserted-by":"publisher","first-page":"e346","DOI":"10.1016\/j.cllc.2018.12.007","volume":"20","author":"L Wang","year":"2019","unstructured":"Wang L, Zhan C, Gu J, et al. Role of skip Mediastinal Lymph Node Metastasis for patients with resectable non-small-cell Lung Cancer: a propensity score matching analysis. Clin Lung Cancer. 2019;20(3):e346\u201355.","journal-title":"Clin Lung Cancer"},{"issue":"10 Pt A","key":"2437_CR16","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1016\/j.ejso.2019.12.015","volume":"46","author":"X Li","year":"2020","unstructured":"Li X, Li X, Fu X, et al. Survival benefit of skip metastases in surgically resected N2 non-small cell lung cancer: a multicenter observational study of a large cohort of the chinese patients. Eur J Surg Oncol. 2020;46(10 Pt A):1874\u201381.","journal-title":"Eur J Surg Oncol"},{"issue":"6","key":"2437_CR17","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1093\/ejcts\/ezaa215","volume":"58","author":"M Chiappetta","year":"2020","unstructured":"Chiappetta M, Lococo F, Leuzzi G, et al. External validation of the N descriptor in the proposed tumour-node-metastasis subclassification for lung cancer: the crucial role of histological type, number of resected nodes and adjuvant therapy. Eur J Cardiothorac Surg. 2020;58(6):1236\u201344.","journal-title":"Eur J Cardiothorac Surg"},{"issue":"4","key":"2437_CR18","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1093\/ejcts\/ezw362","volume":"51","author":"F Guerrera","year":"2017","unstructured":"Guerrera F, Renaud S, Tabb\u00f3 F, et al. Epidermal growth factor receptor mutations are linked to skip N2 lymph node metastasis in resected non-small-cell lung cancer adenocarcinomas. Eur J Cardiothorac Surg. 2017;51(4):680\u20138.","journal-title":"Eur J Cardiothorac Surg"},{"key":"2437_CR19","doi-asserted-by":"publisher","first-page":"749156","DOI":"10.3389\/fsurg.2021.749156","volume":"8","author":"X Wang","year":"2021","unstructured":"Wang X, Guo H, Hu Q, Ying Y, Chen B. The impact of skip vs. non-skip N2 lymph node metastasis on the prognosis of Non-Small-Cell Lung Cancer: a systematic review and Meta-analysis. Front Surg. 2021;8:749156.","journal-title":"Front Surg"},{"issue":"3","key":"2437_CR20","doi-asserted-by":"publisher","first-page":"218","DOI":"10.21037\/atm-20-3513","volume":"9","author":"Z Wang","year":"2021","unstructured":"Wang Z, Cheng J, Huang W, et al. Skip metastasis in mediastinal lymph node is a favorable prognostic factor in N2 lung cancer patients: a meta-analysis. Ann Transl Med. 2021;9(3):218.","journal-title":"Ann Transl Med"},{"issue":"5","key":"2437_CR21","doi-asserted-by":"publisher","first-page":"e423","DOI":"10.1016\/j.cllc.2020.02.027","volume":"21","author":"L Wang","year":"2020","unstructured":"Wang L, Ye G, Xue L, et al. Skip N2 metastasis in Pulmonary Adenocarcinoma: good prognosis similar to N1 disease. Clin Lung Cancer. 2020;21(5):e423\u201334.","journal-title":"Clin Lung Cancer"},{"issue":"5","key":"2437_CR22","doi-asserted-by":"publisher","first-page":"304","DOI":"10.5761\/atcs.oa.20-00289","volume":"27","author":"Y Seyrek","year":"2021","unstructured":"Seyrek Y, Cansever L, Ak\u0131n H, Metin M, Bolat E, Bedirhan MA. The significance of skip Mediastinal Lymph Node Metastasis in the prognosis of patients with resected non-small-cell lung carcinoma: is it really a better N2 Disease Subtype. Ann Thorac Cardiovasc Surg. 2021;27(5):304\u201310.","journal-title":"Ann Thorac Cardiovasc Surg"},{"issue":"3","key":"2437_CR23","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.21037\/jtd.2018.01.176","volume":"10","author":"J Zhao","year":"2018","unstructured":"Zhao J, Li J, Li N, Gao S. Clinical significance of skipping mediastinal lymph node metastasis in N2 non-small cell lung cancer. J Thorac Dis. 2018;10(3):1683\u20138.","journal-title":"J Thorac Dis"},{"issue":"1","key":"2437_CR24","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.bj.2017.01.005","volume":"40","author":"CT Wen","year":"2017","unstructured":"Wen CT, Fu JY, Wu CF, et al. Risk factors for relapse of resectable pathologic N2 non small lung cancer and prediction model for time-to-progression. Biomed J. 2017;40(1):55\u201361.","journal-title":"Biomed J"},{"key":"2437_CR25","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.lungcan.2017.11.014","volume":"115","author":"M Isaka","year":"2018","unstructured":"Isaka M, Kojima H, Takahashi S, Omae K, Ohde Y. Risk factors for local recurrence after lobectomy and lymph node dissection in patients with non-small cell lung cancer: implications for adjuvant therapy. Lung Cancer. 2018;115:28\u201333.","journal-title":"Lung Cancer"},{"issue":"1","key":"2437_CR26","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1093\/ejcts\/ezaa267","volume":"59","author":"K Nakagawa","year":"2021","unstructured":"Nakagawa K, Yoshida Y, Yotsukura M, Watanabe SI. Pattern of recurrence of pN2 non-small-cell lung cancer: should postoperative radiotherapy be reconsidered. Eur J Cardiothorac Surg. 2021;59(1):109\u201315.","journal-title":"Eur J Cardiothorac Surg"},{"issue":"3","key":"2437_CR27","doi-asserted-by":"publisher","first-page":"e283","DOI":"10.3747\/co.27.5899","volume":"27","author":"J Jin","year":"2020","unstructured":"Jin J, Xu Y, Hu X, et al. Postoperative radiotherapy option based on mediastinal lymph node reclassification for patients with pN2 non-small-cell lung cancer. Curr Oncol. 2020;27(3):e283\u201393.","journal-title":"Curr Oncol"},{"key":"2437_CR28","doi-asserted-by":"crossref","unstructured":"Herskovic A, Mauer E, Christos P, Nagar H. Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non-Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database. J Thorac Oncol. 2017. 12(2)","DOI":"10.1016\/j.jtho.2016.09.135"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-023-02437-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-023-02437-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-023-02437-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T08:04:24Z","timestamp":1682669064000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-023-02437-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,28]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2437"],"URL":"https:\/\/doi.org\/10.1186\/s12890-023-02437-0","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,28]]},"assertion":[{"value":"4 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the human subjects committees of the participating sites (The Fourth Hospital of Hebei Medical University) and informed consent was obtained from study participants. All methods were carried out in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and Consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"147"}}